MAPT and Alzheimer disease: In particular, Ondrejcak et al., demonstrated that the administration by intracerebroventricular injection of recombinant aggregated tau protein, or tau protein isolated from AD patients, inhibited hippocampal LTP, suggesting a post-synaptic action for tau oligomers [193].